{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:23:36Z","timestamp":1793125416843,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/2319-4170.110365","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T01:38:34Z","timestamp":1365557914000},"page":"40","source":"Crossref","is-referenced-by-count":148,"title":["Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases"],"prefix":"10.1016","volume":"36","author":[{"given":"Michael","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"key-10.4103\/2319-4170.110365-1","first-page":"236","volume-title":"Deconvoluting mTOR biology","author":"Weber","year":"2012","journal-title":"Cell Cycle"},{"key":"key-10.4103\/2319-4170.110365-2","first-page":"231","volume-title":"Frontier of epilepsy research-mTOR signaling pathway","author":"Cho","year":"2011","journal-title":"Exp Mol Med"},{"key":"key-10.4103\/2319-4170.110365-3","first-page":"21","volume-title":"mTOR: From growth signal integration to cancer, diabetes and ageing","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key-10.4103\/2319-4170.110365-4","first-page":"744","volume-title":"mTOR signaling in disease","author":"Dazert","year":"2011","journal-title":"Curr Opin Cell Biol"},{"key":"key-10.4103\/2319-4170.110365-5","doi-asserted-by":"crossref","unstructured":"Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: Hitting the bull\u2032s-eye for neurological disorders. Oxid Med Cell Longev 2010;3:374-91.","DOI":"10.4161\/oxim.3.6.14787"},{"key":"key-10.4103\/2319-4170.110365-6","doi-asserted-by":"crossref","unstructured":"Bove J, Martinez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat Rev Neurosci 2011;12:437-52.","DOI":"10.1038\/nrn3068"},{"key":"key-10.4103\/2319-4170.110365-7","first-page":"87","volume-title":"The tuberous sclerosis complex","author":"Orlova","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"key-10.4103\/2319-4170.110365-8","first-page":"1345","volume-title":"The tuberous sclerosis complex","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2319-4170.110365-9","first-page":"147","volume-title":"Are cortical tubers epileptogenic.Evidence from electrocorticography?","author":"Major","year":"2009","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-10","first-page":"1305","volume-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","author":"European","year":"1993","journal-title":"Cell"},{"key":"key-10.4103\/2319-4170.110365-11","first-page":"805","volume-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","author":"Van","year":"1997","journal-title":"Science"},{"key":"key-10.4103\/2319-4170.110365-12","first-page":"699","volume-title":"TSC tumour suppressor proteins antagonize amino acid-TOR signalling","author":"Gao","year":"2002","journal-title":"Nat Cell Biol"},{"key":"key-10.4103\/2319-4170.110365-13","first-page":"648","volume-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"key-10.4103\/2319-4170.110365-14","first-page":"13571","volume-title":"Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling","author":"Tee","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2319-4170.110365-15","first-page":"1348","volume-title":"Mutation in TSC2 and activation of mammalian target of rapamycin signaling pathway in renal angiomyolipoma","author":"El-Hashemite","year":"2003","journal-title":"Lancet"},{"key":"key-10.4103\/2319-4170.110365-16","first-page":"213","volume-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models","author":"Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"key-10.4103\/2319-4170.110365-17","first-page":"444","volume-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2319-4170.110365-18","first-page":"490","volume-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2319-4170.110365-19","first-page":"1801","volume-title":"Everolimus for subependymal giant-cell astrocytomas in Tuberous Sclerosis","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2319-4170.110365-20","first-page":"140","volume-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2319-4170.110365-21","first-page":"e23379","volume-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"key":"key-10.4103\/2319-4170.110365-22","doi-asserted-by":"crossref","unstructured":"Haemel AK, O\u2032Brian AL, Teng JM. Topical rapamycin: A novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010;146:715-8.","DOI":"10.1001\/archdermatol.2010.125"},{"key":"key-10.4103\/2319-4170.110365-23","first-page":"453","volume-title":"Association between AKT\/mTOR signaling and malignancy grade of human gliomas","author":"Li","year":"2011","journal-title":"J Neurooncol"},{"key":"key-10.4103\/2319-4170.110365-24","first-page":"5618","volume-title":"AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling","author":"Riemenschneider","year":"2006","journal-title":"Cancer Res"},{"key":"key-10.4103\/2319-4170.110365-25","first-page":"2965","volume-title":"Structural alterations of the epidermal growth factor receptor gene in human gliomas","author":"Wong","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2319-4170.110365-26","first-page":"4183","volume-title":"Somatic mutations of PTEN in glioblastoma multiforme","author":"Wang","year":"1997","journal-title":"Cancer Res"},{"key":"key-10.4103\/2319-4170.110365-27","first-page":"2259","volume-title":"PTEN mutations in gliomas and glioneuronal tumors","author":"Duerr","year":"1998","journal-title":"Oncogene"},{"key":"key-10.4103\/2319-4170.110365-28","first-page":"799","volume-title":"Human brain tumor xenografts in nuce mice as a chemotherapy model","author":"Houchens","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"key-10.4103\/2319-4170.110365-29","first-page":"7291","volume-title":"Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy","author":"Eshleman","year":"2002","journal-title":"Cancer Res"},{"key":"key-10.4103\/2319-4170.110365-30","first-page":"1","volume-title":"Mechanisms of action of rapamycin in gliomas","author":"Heimberger","year":"2005","journal-title":"Neuro-oncol"},{"key":"key-10.4103\/2319-4170.110365-31","first-page":"292","volume-title":"Rapamycin-mediated mTOR inhibition attenuates surviving and sensitizes glioblastoma cells to radiation","author":"Anandharaj","year":"2011","journal-title":"Acta Biochim Biophys Sin"},{"key":"key-10.4103\/2319-4170.110365-32","first-page":"357","volume-title":"North American Brain Tumor Consortium and the National Cancer Institute.Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme","author":"Chang","year":"2005","journal-title":"Invest New Drugs"},{"key":"key-10.4103\/2319-4170.110365-33","first-page":"5294","volume-title":"North Central Cancer Treatment Group.Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/2319-4170.110365-34","first-page":"341","volume-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","author":"Fan","year":"2006","journal-title":"Cancer Cell"},{"key":"key-10.4103\/2319-4170.110365-35","first-page":"349","volume-title":"Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1\/2 inhibitors","author":"Fan","year":"2012","journal-title":"Methods Mol Biol"},{"key":"key-10.4103\/2319-4170.110365-36","first-page":"8","volume-title":"Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development","author":"Wong","year":"2008","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-37","first-page":"231","volume-title":"Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis","author":"McDaniel","year":"2011","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/2319-4170.110365-38","first-page":"27","volume-title":"Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies","author":"Wong","year":"2010","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-39","first-page":"5422","volume-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-40","first-page":"1070","volume-title":"Regulable neural progenitor-specific TSC1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex","author":"Goto","year":"2011","journal-title":"PNAS"},{"key":"key-10.4103\/2319-4170.110365-41","first-page":"445","volume-title":"TSC2 gene inactivation causes a more severe epilepsy phenotype than TSC1 inactivation in a mouse model of tuberous sclerosis complex","author":"Zeng","year":"2011","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/2319-4170.110365-42","first-page":"369","volume-title":"Neuronal and glia abnormalities in TSC1-deficient forebrain and partial rescue by rapamycin","author":"Carson","year":"2012","journal-title":"Neurobiol Dis"},{"key":"key-10.4103\/2319-4170.110365-43","first-page":"843","volume-title":"Reversal of learning deficits in a TSC2+\/- mouse model of tuberous sclerosis","author":"Ehninger","year":"2008","journal-title":"Nat Med"},{"key":"key-10.4103\/2319-4170.110365-44","first-page":"477","volume-title":"Rapamycin reduces seizure frequency in Tuberous Sclerosis Complex","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"key":"key-10.4103\/2319-4170.110365-45","first-page":"83","volume-title":"Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex","author":"Perek-Poinik","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"key-10.4103\/2319-4170.110365-46","unstructured":"Wilfong A, Krueger DA, Holland-Bouley K, Anderson AE, Agricola K, Schultz RJ, et al. Everolimus improves seizure control in tuberous sclerosis complex. American Epilepsy Society Meeting Abstracts 2011; Late-breaking Abstract #3.329."},{"key":"key-10.4103\/2319-4170.110365-47","first-page":"12923","volume-title":"mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo","author":"Kwon","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2319-4170.110365-48","first-page":"389","volume-title":"Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia","author":"Ljungberg","year":"2009","journal-title":"Dis Model Mech"},{"key":"key-10.4103\/2319-4170.110365-49","first-page":"2065","volume-title":"Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice","author":"Sunnen","year":"2011","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-50","first-page":"1773","volume-title":"Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice","author":"Zhou","year":"2009","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-51","first-page":"1591","volume-title":"STRADa deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice","author":"Orlova","year":"2010","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2319-4170.110365-52","first-page":"478","volume-title":"mTOR cascade activation distinguishes tubers from focal cortical dysplasia","author":"Baybis","year":"2004","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2319-4170.110365-53","first-page":"165","volume-title":"Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells","author":"Schick","year":"2007","journal-title":"Brain Pathol"},{"key":"key-10.4103\/2319-4170.110365-54","first-page":"29","volume-title":"Focal cortical dysplasia of Taylor\u2032s balloon cell type: Mutational analysis of the TSC1 gene indicates a pathogenic relationship to Tuberous Sclerosis","author":"Becker","year":"2002","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2319-4170.110365-55","first-page":"559","volume-title":"Increased frequency of distinct TSC2 alleleic variants in focal cortical dysplasias with balloon cells and mineralization","author":"Schonberger","year":"2009","journal-title":"Neuropathology"},{"key":"key-10.4103\/2319-4170.110365-56","first-page":"1396","volume-title":"Focal cortical dysplasia: A genotype-phenotype analysis of polymorphisms and mutations in the TSC genes","author":"Gumbinger","year":"2009","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-57","first-page":"43","volume-title":"Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor\u2032s balloon cell type","author":"Grajkowski","year":"2008","journal-title":"Folia Neuropathol"},{"key":"key-10.4103\/2319-4170.110365-58","first-page":"1136","volume-title":"Hamartin variants that are frequent in focal dysplasias and cortical tubers have reduced tuberin binding and aberrant subcellular distribution in vitro","author":"Lugnier","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.4103\/2319-4170.110365-59","first-page":"420","volume-title":"Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia","author":"Ljungberg","year":"2006","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2319-4170.110365-60","first-page":"510","volume-title":"Insulin signaling pathways in cortical dysplasia and TSC-tubers: Tissue microarray analysis","author":"Miyata","year":"2004","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2319-4170.110365-61","first-page":"8259","volume-title":"Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy","author":"Buckmaster","year":"2009","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-62","first-page":"6964","volume-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","author":"Zeng","year":"2009","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-63","first-page":"193","volume-title":"Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy","author":"Huang","year":"2010","journal-title":"Neurobiol Dis"},{"key":"key-10.4103\/2319-4170.110365-64","first-page":"1254","volume-title":"Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation","author":"van","year":"2012","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-65","first-page":"939","volume-title":"Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury","author":"Chen","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"key-10.4103\/2319-4170.110365-66","first-page":"e35885","volume-title":"The interaction between early life epilepsy and autistic-like behavioral consequences: A role for the mammalian target of rapamycin (mTORC1) pathway","author":"Talos","year":"2012","journal-title":"PLoS ONE"},{"key":"key-10.4103\/2319-4170.110365-67","first-page":"322","volume-title":"A pulse rapamycin therapy for infantile spasms and associated cognitive decline","author":"Raffo","year":"2011","journal-title":"Neurobiol Dis"},{"key":"key-10.4103\/2319-4170.110365-68","first-page":"86","volume-title":"Rapamycin is a neuroprotective treatment for traumatic brain injury","author":"Erlich","year":"2007","journal-title":"Neurobiol Dis"},{"key":"key-10.4103\/2319-4170.110365-69","first-page":"2337","volume-title":"Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy","author":"Buckmaster","year":"2011","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-70","first-page":"105","volume-title":"Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy","author":"Sliwa","year":"2012","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/2319-4170.110365-71","first-page":"1666","volume-title":"Validation of the rat model of cryptogenic infantile spasms","author":"Chachua","year":"2011","journal-title":"Epilepsia"},{"key":"key-10.4103\/2319-4170.110365-72","first-page":"268","volume-title":"Deregulated mTOR-mediated translation in intellectual disability","author":"Troca-Marin","year":"2012","journal-title":"Prog Neurobiol"},{"key":"key-10.4103\/2319-4170.110365-73","first-page":"467","volume-title":"A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus","author":"Tang","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2319-4170.110365-74","first-page":"3791","volume-title":"Selective pharmacogenetic inhibition of mammalian target of rapamycin complex 1 (mTORC1) blocks long-term synaptic plasticity and memory storage","author":"Stoica","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2319-4170.110365-75","first-page":"11300","volume-title":"Control of dendritic arborization by the phosphoinositide-3\u2032- kinase-Akt-mammalian target of rapamycin pathway","author":"Jaworski","year":"2005","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-76","first-page":"11288","volume-title":"Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways","author":"Kumar","year":"2005","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-77","first-page":"48","volume-title":"Dendritic pathology in mental retardation: From molecular genetics to neurobiology","author":"Dierssen","year":"2006","journal-title":"Genes Brain Behav"},{"key":"key-10.4103\/2319-4170.110365-78","first-page":"694","volume-title":"Dysregulation of mTOR signaling in fragile X syndrome","author":"Sharma","year":"2010","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-79","first-page":"332","volume-title":"Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome","author":"Hoeffer","year":"2012","journal-title":"Gene Brain Behav"},{"key":"key-10.4103\/2319-4170.110365-80","first-page":"9445","volume-title":"An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down\u2032s syndrome","author":"Troca-Marin","year":"2011","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-81","first-page":"1182","volume-title":"Reduced AKT\/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model","author":"Ricciardi","year":"2011","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/2319-4170.110365-82","first-page":"13107","volume-title":"Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments","author":"Caccamo","year":"2010","journal-title":"J Biol Chem"},{"key":"key-10.4103\/2319-4170.110365-83","first-page":"4211","volume-title":"Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer\u2032s disease brain","author":"Li","year":"2005","journal-title":"FEBS J"},{"key":"key-10.4103\/2319-4170.110365-84","first-page":"e9979","volume-title":"Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer\u2032s disease","author":"Spilman","year":"2010","journal-title":"PloS One"},{"key":"key-10.4103\/2319-4170.110365-85","first-page":"585","volume-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","author":"Ravikumar","year":"2004","journal-title":"Nat Genet"},{"key":"key-10.4103\/2319-4170.110365-86","doi-asserted-by":"crossref","unstructured":"Floto RA, Sarkar S, Perlstein EO, Kampmann B, Shreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promotes autophagy, reduce toxicity in Huntington\u2032s Disease models and enhance killing of mycobacteria by macrophages. Autophagy 2007;3;620-2.","DOI":"10.4161\/auto.4898"},{"key":"key-10.4103\/2319-4170.110365-87","first-page":"1166","volume-title":"Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2032s disease","author":"Malagelada","year":"2010","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-88","first-page":"12535","volume-title":"Pathogenic lysosomal depletion in Parkinson\u2032s disease","author":"Dehav","year":"2010","journal-title":"J Neurosci"},{"key":"key-10.4103\/2319-4170.110365-89","first-page":"252","volume-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","author":"Boulay","year":"2004","journal-title":"Cancer Res"},{"key":"key-10.4103\/2319-4170.110365-90","first-page":"14","volume-title":"Comparison of three rapamycin dosing schedules in A\/J Tsc2+\/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors","author":"Woodrum","year":"2010","journal-title":"J Transl Med"},{"key":"key-10.4103\/2319-4170.110365-91","first-page":"1059","volume-title":"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","author":"Rivera","year":"2011","journal-title":"Mol Cancer Ther"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T21:55:24Z","timestamp":1539726924000},"score":1,"resource":{"primary":{"URL":"http:\/\/biomedj.cgu.edu.tw\/pdfs\/2013\/36\/2\/images\/BiomedJ_2013_36_2_40_110365.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"alternative-id":["110365"],"URL":"https:\/\/doi.org\/10.4103\/2319-4170.110365","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}